Skip to main content
. Author manuscript; available in PMC: 2018 May 29.
Published in final edited form as: Cell Chem Biol. 2018 Feb 22;25(4):460–470.e6. doi: 10.1016/j.chembiol.2018.01.013

Figure 5. SRPK1 Inhibitors Promote VEGF-A165b Expression by Inducing Alternative Splicing of the VEGF Pre-mRNA.

Figure 5

(A) Analysis of SR protein phosphorylation levels probed with mAb104 in HeLa cells following treatment with indicated compounds at 200 nM with or without washout. The ratio of remained phosphorylation SR protein upon the compound treatment versus actin was quantified. Standard deviation was calculated using the built-in stdev function in Excel.

(B) Effects of knock down of SRPK1 and/or SRPK2 on VEGF pre-mRNA splicing. VEGF-A165a and VEGF-A165b are indicated. No change was detected with SRPK1 overexpression. The VEGF-A165b/(VEGF-A165a + VEGF-A165b) ratios were quantified. Standard deviation was calculated using the built-in stdev function in Excel.

(C) Dosage-dependent effects of SRPKIN-1 on VEGF pre-mRNA splicing. The VEGF-A165b/(VEGF-A165a + VEGF-A165b) ratios were quantified. (D) Elevated expression of VEGF-A165b protein upon treatment with JH-VII-139-1 or SRPKIN-1.

See also Figure S1.